Iranian journal of Pediatric Hematology and Oncology
Iranian journal of Pediatric Hematology and Oncology
Iran J Ped Hematol Oncol
Medical Sciences
http://ijpho.ssu.ac.ir
1
admin
2008-8892
2228-6993
8
7
14
8888
13
en
jalali
1402
4
1
gregorian
2023
7
1
13
3
online
1
fulltext
en
The Management and Approach to Osteosarcoma in Children: A Mini-review Article
عمومى
General
مروری
Review
<div style="border:double windowtext 1.5pt; padding:1.0pt 4.0pt 1.0pt 4.0pt"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,"sans-serif""><span style="font-size:10.0pt"><span style="font-family:"Times New Roman","serif"">Osteosarcoma (OS) is the most common type of primary malignant bone tumor. The onset of OS is associated with local pain and swelling as well as joint dysfunction, occasionally. The most common location for OS is around the knee joint. These patients often tend to receive medical attention following physical exercise and trauma. The affected population is mainly teenagers, children, and young adults with age range of 10-30 years. </span></span></span></span></span><br>
<span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,"sans-serif""><span style="font-size:10.0pt"><span style="font-family:"Times New Roman","serif"">OS can be diagnosed via different approaches. The main serum markers for pediatric OS are insulin</span></span><span style="font-size:10.0pt"><span style="font-family:"Times New Roman","serif"">‑</span></span><span style="font-size:10.0pt"><span style="font-family:"Times New Roman","serif"">like growth factor (IGF</span></span><span style="font-size:10.0pt"><span style="font-family:"Times New Roman","serif"">‑</span></span><span style="font-size:10.0pt"><span style="font-family:"Times New Roman","serif"">1 and IGFBP</span></span><span style="font-size:10.0pt"><span style="font-family:"Times New Roman","serif"">‑</span></span><span style="font-size:10.0pt"><span style="font-family:"Times New Roman","serif"">3), anti</span></span><span style="font-size:10.0pt"><span style="font-family:"Times New Roman","serif"">‑</span></span><span style="font-size:10.0pt"><span style="font-family:"Times New Roman","serif"">ki57 antibody, tumor necrosis factor (TNF)</span></span><span style="font-size:10.0pt"><span style="font-family:"Times New Roman","serif"">‑</span></span><span style="font-size:10.0pt"><span style="font-family:"Times New Roman","serif"">β</span></span><span style="font-size:10.0pt"><span style="font-family:"Times New Roman","serif""> and sTNF</span></span><span style="font-size:10.0pt"><span style="font-family:"Times New Roman","serif"">‑</span></span><span style="font-size:10.0pt"><span style="font-family:"Times New Roman","serif"">R, T3, CD44, vascular endothelial growth factor, serum amyloid A, CXC chemokines, bone alkalin phosphatase, Interleukin (IL</span></span><span style="font-size:10.0pt"><span style="font-family:"Times New Roman","serif"">‑</span></span><span style="font-size:10.0pt"><span style="font-family:"Times New Roman","serif"">2, IL</span></span><span style="font-size:10.0pt"><span style="font-family:"Times New Roman","serif"">‑</span></span><span style="font-size:10.0pt"><span style="font-family:"Times New Roman","serif"">4, IL</span></span><span style="font-size:10.0pt"><span style="font-family:"Times New Roman","serif"">‑</span></span><span style="font-size:10.0pt"><span style="font-family:"Times New Roman","serif"">8), interferon gamma (IFN-</span></span><span style="font-size:10.0pt"><span style="font-family:"Times New Roman","serif"">γ</span></span><span style="font-size:10.0pt"><span style="font-family:"Times New Roman","serif"">), TNF</span></span><span style="font-size:10.0pt"><span style="font-family:"Times New Roman","serif"">‑</span></span><span style="font-size:10.0pt"><span style="font-family:"Times New Roman","serif"">α</span></span><span style="font-size:10.0pt"><span style="font-family:"Times New Roman","serif"">, and free polyamines. </span></span></span></span></span><br>
<span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,"sans-serif""><span style="font-size:10.0pt"><span style="font-family:"Times New Roman","serif"">Given that there is no comprehensive review literature regarding OS management in our country, this study aimed to assess a survey on the management and approach of OS in children. In this regard, we have discussed the epidemiology, etiology, type, clinical feature, diagnosis, and OS therapy. </span></span></span></span></span></div>
Childhood, Etiology, Malignancy, Osteosarcoma, Serum Marker
214
221
http://ijpho.ssu.ac.ir/browse.php?a_code=A-10-614-6&slc_lang=en&sid=1
Maryam sadat
Yazdanparast
maryyamyazdanparasst@gmail.com